HER2-low scoring → T-DXd
Reading the faint end of the HER2 stain decides who gets Enhertu.
IHC 1+/2+ (low) and IHC 0 with faint staining (ultralow) predict T-DXd benefit in HR+ and TNBC. Reproducibility at the low end is poor; AI-assisted HER2 scoring is being validated.
Pages like this
not linked directly; found by shared links- IdeaCalibrated reference slides so every lab scores HER2-low the same way
Shares DESTINY-Breast06, DESTINY-Breast04, AI quantification of HER2-low and HER2-ultralow, HER2-low and HER2-ultralow.
- PersonGiuseppe Curigliano
Shares DESTINY-Breast06, HER2-low and HER2-ultralow, Trastuzumab deruxtecan, Triple-negative breast cancer (TNBC).
- IdeaRandomised trials to test whether biomarker-negative patients really do not benefit
Shares DESTINY-Breast06, HER2-low and HER2-ultralow, Trastuzumab deruxtecan.
- IdeaRe-test the metastasis, not the old primary, before every change of treatment
Shares HER2-low and HER2-ultralow, Histopathology & immunohistochemistry, HR-positive / HER2-negative breast cancer.
- Key paperDESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer
Shares DESTINY-Breast06, HER2-low and HER2-ultralow, Histopathology & immunohistochemistry, Trastuzumab deruxtecan.
- Key paperDESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group
Shares DESTINY-Breast04, HER2-low and HER2-ultralow, Histopathology & immunohistochemistry, Trastuzumab deruxtecan.
- IdeaA standard evaluation pathway for AI-assisted pathology, from reader study to deployment
Shares AI quantification of HER2-low and HER2-ultralow, Histopathology & immunohistochemistry.
- PairingCaution: TOP1 ADC immediately after TOP1 ADC
Shares Trastuzumab deruxtecan, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.